TRT and cardiac health: what the evidence actually says

What's this video probably claiming?

Based on the hashtags #cardiac, #ETP, and #TRT context, this creator, who presents as a healthcare worker, is likely discussing testosterone replacement therapy in relation to cardiovascular health. The #ETP hashtag suggests she may be referencing an employee training program or a specific clinical protocol. The framing around loving healthcare work and ongoing learning implies she is sharing clinical education content, possibly defending TRT's cardiac safety profile or explaining how providers evaluate cardiac risk before prescribing testosterone. In the current TikTok TRT discourse, this usually means someone is pushing back on the old FDA black-box fears or claiming testosterone is actually heart-protective. That is a genuinely contested area, and the devil is very much in the details, including which patient population, which formulation, and what dose range we are talking about.

What does the science actually show?

The TRAVERSE trial (Lincoff et al., 2023, NEJM) was the landmark randomized controlled trial the field had been waiting for. It enrolled 5,246 men with hypogonadism and pre-existing cardiovascular disease or high cardiac risk, and found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events over a median follow-up of 33 months. That is reassuring, but non-inferiority is not the same as cardioprotective. The trial also found a statistically significant increase in atrial fibrillation (3.5% vs 2.4%), pulmonary embolism, and acute kidney injury in the testosterone arm. Earlier meta-analyses, including Xu et al. (2013, BMJ), had flagged elevated cardiovascular risk, particularly in older men and those with existing disease. The picture is nuanced: TRT is probably safe for appropriately selected hypogonadal men, but it is not a cardiac health booster.

Where does the social media noise diverge from clinical reality?

TikTok TRT content tends to flatten the risk-benefit conversation into a binary. Either testosterone is dangerous and suppressed by Big Pharma, or it is the solution to men's health decline and perfectly safe. Both framings are wrong. The clinical reality is that patient selection matters enormously. A 35-year-old with confirmed hypogonadism and no cardiac history has a very different risk profile than a 58-year-old with prior MI seeking testosterone for energy optimization. The TRAVERSE data applies to the high-risk population, yet social media creators often cite it universally as a blanket safety clearance. The atrial fibrillation signal in TRAVERSE is almost never mentioned in creator content. Neither is the fact that hematocrit elevation, which occurs in roughly 20-30% of TRT patients per Bhasin et al. (2018, NEJM), increases blood viscosity and thromboembolic risk, which is a real cardiac concern that requires monitoring.

What should you actually know?

If you are a patient considering TRT and you have cardiac risk factors, the conversation with your provider should include a baseline EKG, hematocrit levels, and a clear discussion of the TRAVERSE trial findings, including the atrial fibrillation data. The Endocrine Society clinical guidelines (Bhasin et al., 2018) recommend TRT only for men with confirmed low testosterone by validated morning serum levels, not for symptom optimization alone in eugonadal men. For women, the evidence base is even thinner. Female TRT for hypogonadism is an active area of research, but large-scale cardiac safety RCTs in women simply do not exist yet. Any creator discussing cardiac safety of TRT in women should be held to a very high standard of evidence transparency, because the data to support broad claims is not there. Regular monitoring, individualized dosing, and physician oversight are not optional add-ons. They are the clinical standard for a reason.